Exploring the acceptability, appropriateness, feasibility and satisfaction of an implementation strategy for out-of-HOspital administration of the Long-Acting combination of cabotegravir and rilpivirine as an optional therapy for HIV in Spain (the HOLA study)—a hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study: study protocol

Exploring the acceptability, appropriateness, feasibility and satisfaction of an implementation strategy for out-of-HOspital administration of the Long-Acting combination of cabotegravir and rilpivirine as an optional therapy for HIV in Spain (the HOLA study)—a hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study: study protocol

Introduction The HOLA study is a 12-month randomised, hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study including virologically suppressed people living with HIV (PWH). HOLA, which started in September 2023, evaluates acceptability, appropriateness, feasibilit...

Full description

Saved in:
Bibliographic Details
Main Authors: Jordi Puig, Vicenç Falcó, Cristina Miranda, Francis Ruiz, Julián Olalla, Àngel Rivero, Patricia Álvarez-Lopez, Eugenia Negredo, Diana Hernández-Sánchez, Javier Jusmet, Miguel Ángel Cuerda Palomo, Ana Belén Flores de la Cruz, José Manuel Pavón, Nadia Llavero, David Campany, Vicente Faus, Claudia Broto-Cortés, Lucía Bailón, Dámaris Aguilar, David Rovira
Format: Article
Language:English
Published: BMJ Publishing Group 2025-04-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/4/e088514.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items